FindTrial
Sign In

Effectiveness of oxytocin intranasal on reducing alcohol consumption and depression syndrome in a patient with oropharyngeal carcinoma, a quasi-experimental single-case design structure

Effectiveness of oxytocin intranasal on reducing alcohol consumption and depression syndrome in a patient with oropharyngeal carcinoma, a quasi-experimental single-case design structure

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180417001
Enrollment
1
Registered
2018-04-17
Start date
2014-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All the data of this study were collected after agreement with the patient&#44

Interventions

Oxytocin intranasal spray (Syntocinon(®)
Novartis&#44
Basel&#44
Switzerland) was including oxytocin plus glycerol&#44
sorbitol&#44
benzyl alcohol and distilled water&#44
that was contained in an amber 7 mL glass nasal spray with a metered pump. Placebo sprays had the same combination but did not contain oxytocin. Each pump spray delivered 50 μL of OT (9 IU) or placeb
Experimental Drug
oxytocin intranasal

Sponsors

none
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: single-case design structure

Exclusion criteria

Exclusion criteria: single-case design structure

Design outcomes

Primary

MeasureTime frame
Alcohol consumption rate 14 months and 44 evaluations Alcohol Use Disorders Identification Test (AUDIT)—

Secondary

MeasureTime frame
depression index 14 months and 44 evaluations Beck Depression Inventory (BDI)—

Countries

iran

Contacts

Public Contactbijan pirnia

Bijan Center

b.pirnia@usc.ac.ir+9802122081450

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026